- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Genitourinary tract infection
Lower respiratory tract infections
Skin and soft tissue infections
Upper respiratory tract infections
1g twice daily (up to a maximum of 4g daily), depending on the severity of infection.
Streptococcal pharyngitis and tonsilitis
Doses may be reduced to 1g once daily for at least ten days.
Children aged 6 to 18 years, weighing over 40kg
(See Dosage; Adult)
Children aged 6 to 18 years, weighing less than 40kg
30mg/kg to 50mg/kg daily, divided into two daily doses.
The following doses may be suitable:
Children aged 6 to 18 years, over 40kg
500mg to 1g twice a day (1g once daily for skin, soft-tissue and uncomplicated urinary-tract infections).
Children aged 6 to 18 years, less than 40kg
500mg twice a day.
30mg/kg once daily over at least ten days.
Patients with Renal Impairment
Dosage should be adjusted according to estimated glomerular filtration rate (eGFR).
No dosage adjustment is required in patients with eGFR greater than 50ml/minute/1.73 metre squared.
Dosage schedule for adults with renal impairment is suggested below:
eGFR 25 to 50 ml/minute/1.73 metre squared
1g initially followed by 500mg to 1g every 12 hours.
eGFR 10 to 25 ml/minute/1.73 metre squared
1g initially followed by 500mg to 1g every 24 hours.
eGFR 0 to 10 ml/minute/1.73 metre squared
1g initially followed by 500mg to 1g every 36 hours.
Cefadroxil is removed by haemodialysis. An additional dose of 500mg to 1g should be given at the end of haemodialysis (in adults).
Children under 6 years
Precautions and Warnings
History of allergies including anaphylaxis
History of gastrointestinal disorder
Renal impairment - eGFR below 50ml/ minute/ 1.73m squared
Advise ability to drive/operate machinery may be affected by side effects
Before initiating therapy enquire about previous hypersensitivity reactions
Consult national/regional policy on the use of anti-infectives
Monitor liver function on prolonged therapy
Monitor renal function during prolonged/high dose therapy
Perform blood counts on prolonged use of this treatment
Consider pseudomembranous colitis if patient presents with diarrhoea
Prolonged use may result in superinfection with non-susceptible organisms
May cause false positive Coomb's test and glycosuria test
Neonate exposed in utero: Risk of false positive Coomb's test
Discontinue if drug-related rash or other hypersensitivity reactions occur
Pregnancy and Lactation
Safety of cefadroxil administration during pregnancy has not been established. Animal studies and clinical experience have not shown any evidence of teratogenicity. Cephalosporins are usually considered safe to use during pregnancy.
Cephalosporins cross the placenta, and can reach therapeutic levels in amniotic fluid and fetal tissues.
The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14-17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Use with caution while breastfeeding. Cefadroxil is excreted in low concentrations in human breast milk.
Occasionally, disruption of the infant's gastrointestinal flora, resulting in diarrhoea or thrush, has been reported with cephalosporins, however, these effects have not been adequately evaluated.
Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
Increase in serum transaminases
Serum sickness-like reactions
Toxic epidermal necrolysis
Effects on Laboratory Tests
A false positive reaction for glucose in the urine may occur with Benedict's or Fehling's solutions. This does not occur with enzyme-based tests.
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Last Full Review Date: February 2013
Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.
Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, 9th edition (2011) ed. Briggs, G., Freeman, R. and Yaffe, S. Lippincott Williams & Wilkins, Philadelphia.
Summary of Product Characteristics: Cefadroxil 500mg Capsules. Sandoz Ltd. Revised January 2012
NICE Evidence Services Available at: www.nice.org.uk Last accessed: 22 June 2017
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.